Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
USRE49192E1 · kind E1 · reissue
Assignee
Inventors
Key dates
| Filing date | May 30, 2019 |
| Grant date | Aug 30, 2022 |
| Priority date | — |
| Expiry date | May 30, 2039 |
Classification
- Technology area (CPC —)General
Abstract
The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and low level of sialylated glycoform. The present invention also relates to the use of these antibodies in the treatment, prevention or management of disease or disorder, such as cancer, especially a B-cell malignancy, and auto-immune disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.